Dr Lucy Gildea Appointed To Power Up Mary Kay’s Global Brand

KUALA LUMPUR, Feb 7 (Bernama) -- The iconic beauty and entrepreneurship company, Mary Kay Inc has appointed Dr Lucy Gildea as its Chief Brand and Scientific Officer to empower future growth.

Mary Kay Chief Executive Officer, Ryan Rogers in a statement said Dr Gildea’s expertise in science and beauty innovation and customer-centric approach will lead a strategic chapter of the company’s transformation into the future.

“The new Global Brand and Science organisation will contribute to our mutual business success by enabling our Independent Beauty Consultants to share a transformative brand experience with their customers and thrive as personal beauty advisors, thus reinforcing the unique value proposition of direct selling,” added Rogers, who is also the grandson of Mary Kay Ash.

Meanwhile, Dr Gildea said: “I look forward to maximising synergies across our teams to captivate our Independent Beauty Consultants and invite a new generation of consumers to fall in love with our brand.”

Together with her freshly designed cross-functional team, Dr Gildea will pioneer a new operating model to enhance Mary Kay’s global brand and science, aiming for growth and customer loyalty in over 40 markets.

In her expanded role, she will shape a powerful brand identity, image, and strategy consistent across all platforms and geographies supported by an impactful product portfolio embracing the ever-evolving needs of consumers.

She and her team will activate the brand through engagement strategies harnessing the power of next-gen entrepreneurs and resonant brand storytelling to win the hearts and minds of consumers.

Since joining Mary Kay in 2017, Dr Gildea has focused on modernising and enhancing the company's competitiveness through product innovation and by improving organisational efficiencies.

A passionate science, technology, engineering, and mathematics (STEM) advocate for women and girls, Dr Gildea serves as a Board Member at Baylor Scott & White Dallas Foundation and a Board Advisor at Baylor Scott & White Charles A. Sammons Cancer Center.

-- BERNAMA